Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-acting HIV Treatments: Study Design, Logistics, and Access.
Murdock NA, Alajaji NE, Schaefer R, Boone CA, Campo RE, Dore GJ, Gandhi M, Gorospe JR, Gulick RM, Hodder SL, Liu J, Rhee MS, Rooney JF, Vannappagari V, Wilkin T, Miller V. Murdock NA, et al. Among authors: vannappagari v. Open Forum Infect Dis. 2024 Jun 15;11(7):ofae337. doi: 10.1093/ofid/ofae337. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 38983711 Free PMC article. Review.
Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project.
Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, Duerr A, Glidden DV, Hughes JP, Murray J, Robertson MN, Zinserling J, Lau J, Miller V; Forum for Collaborative Research Recency Assay Working Group. Parkin N, et al. Clin Pharmacol Ther. 2023 Jul;114(1):29-40. doi: 10.1002/cpt.2830. Epub 2023 Jan 5. Clin Pharmacol Ther. 2023. PMID: 36550769 Review.
Promising results of HIV prevention trials highlight the benefits of collaboration in global health: The perspective of the Forum HIV Recency Assay Working Group.
Schaefer R, Donaldson L, Leus M, Osakwe CE, Chimukangara B, Dalal S, Duerr A, Gao F, Glidden DV, Grinsztejn B, Justman J, Kumwenda G, Laeyendecker O, Lee HY, Maldarelli F, Mayer KH, Murray J, Parekh BS, Rice B, Robertson MN, Saito S, Vannappagari V, Warren M, Zeballos D, Zinserling J, Miller V. Schaefer R, et al. Among authors: vannappagari v. PLOS Glob Public Health. 2024 Oct 24;4(10):e0003878. doi: 10.1371/journal.pgph.0003878. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39446892 Free PMC article. No abstract available.
Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus.
Chammartin F, Mocroft A, Egle A, Zangerle R, Smith C, Mussini C, Wit F, Vehreschild JJ, d'Arminio Monforte A, Castagna A, Bailly L, Bogner J, de Wit S, Matulionyte R, Law M, Svedhem V, Tallada J, Garges HP, Marongiu A, Borges ÁH, Jaschinski N, Neesgaard B, Ryom L, Bucher HC; RESPOND Study Group. Chammartin F, et al. Clin Infect Dis. 2024 Apr 10;78(4):995-1004. doi: 10.1093/cid/ciad671. Clin Infect Dis. 2024. PMID: 38092042 Free PMC article.
Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration.
Teichner P, Chamay N, Elliot E, Pascual-Bernáldez M, Merrill D, Garris C, D'Amico R, Felizarta C, Torres E, Van Solingen-Ristea R, Baugh B, Patel P, Vannappagari V, Dakhia S, Polli JW, Garside L, Grove R, Thiagarajah S, Birmingham E, van Wyk J. Teichner P, et al. Among authors: vannappagari v. Open Forum Infect Dis. 2024 May 25;11(6):ofae282. doi: 10.1093/ofid/ofae282. eCollection 2024 Jun. Open Forum Infect Dis. 2024. PMID: 38882931 Free PMC article. Clinical Trial.
Variation in Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among US Men Who Have Sex with Men: A Latent Class Analysis.
Beckham SW, Sanchez T, Fowler R, Zlotorzynska M, Rai M, Sullivan P, Vannappagari V, Sarkar S, Glick JL, Rinehart AR, Rawlings K, Bridges JFP. Beckham SW, et al. Among authors: vannappagari v. AIDS Patient Care STDS. 2023 Oct;37(10):495-503. doi: 10.1089/apc.2023.0109. AIDS Patient Care STDS. 2023. PMID: 37862078 Free PMC article.
Preference for Long-Acting HIV Prevention Methods Among Transgender Women Vulnerable to HIV in Eastern and Southern United States: Findings from the LITE Study.
Cooney EE, Stevenson M, Aguayo-Romero RA, Valera G, Poteat TC, Mayer KH, Beyrer C, Althoff KN, Radix AE, Wawrzyniak AJ, Cannon CM, Schneider JS, Brown CA, Vannappagari V, Ragone L, de Ruiter A, Reisner SL, Wirtz AL. Cooney EE, et al. Among authors: vannappagari v. AIDS Behav. 2024 Dec 5. doi: 10.1007/s10461-024-04561-2. Online ahead of print. AIDS Behav. 2024. PMID: 39636555
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus.
Greenberg L, Ryom L, Neesgaard B, Wandeler G, Staub T, Gisinger M, Skoll M, Günthard HF, Scherrer A, Mussini C, Smith C, Johnson M, De Wit S, Necsoi C, Pradier C, Wit F, Lehmann C, d'Arminio Monforte A, Miró JM, Castagna A, Spagnuolo V, Sönnerborg A, Law M, Hutchinson J, Chkhartishvili N, Bolokadze N, Wasmuth JC, Stephan C, Vannappagari V, Rogatto F, Llibre JM, Duvivier C, Hoy J, Bloch M, Bucher HC, Calmy A, Volny Anne A, Pelchen-Matthews A, Lundgren JD, Peters L, Bansi-Matharu L, Mocroft A; RESPOND (International Cohort Consortium of Infectious Diseases) Study Group. Greenberg L, et al. Among authors: vannappagari v. Clin Infect Dis. 2021 Oct 5;73(7):e2323-e2333. doi: 10.1093/cid/ciaa1878. Clin Infect Dis. 2021. PMID: 33354721 Free PMC article.
73 results